We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The Janssen Pharmaceutical Companies of Johnson & Johnson announced the World Health Organization (WHO) will include abiraterone acetate (ZYTIGA®) for the treatment of metastatic castration-resistant prostate cancer (mCRPC), in the updated Essential Medic